Shares of Bio-Techne (NASDAQ:TECH) were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share were up 87.00% over the past year to $1.87, which beat the estimate of $1.70.
Revenue of $259,028,000 rose by 47.31% year over year, which beat the estimate of $244,620,000.
Outlook
Earnings guidance hasn’t been issued by the company for now.
Revenue guidance hasn’t been issued by the company for now.
How To Listen To The Conference Call
Date: Aug 05, 2021
Time: 09:00 AM
ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1481160&tp_key=8a365aa878
Recent Stock Performance
52-week high: $488.23
52-week low: $228.66
Price action over last quarter: Up 15.06%
Company Profile
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
